incretin and glp-1 The role of amylin hormones (GLP-1 and GIP) in maintaining Incretin physiology and pathophysiology from

Research published in Science Direct found that nutritional deficiencies were diagnosed in 12.7% of patients within six months of starting GLP-1 receptor agonist therapy, and that number climbed to 22.4% within twelve months

Emerging evidence suggests GLP-1 receptor agonists are associated with increased gallstone risk, with clinical trials showing gallbladder disorders in approximately 2.6% of patients on semaglutide versus 1.2% on placebo

Establishing conscious nutritional changes and regular physical activity is absolutely critical for maintaining your fat loss and preventing weight rebound if medication is ever discontinued

A Word from Our Chief Science Officer

aligned with your volume, replenishment cadence, and operational workflow